

Leishmaniasis

SYRIAN ARAB REPUBLIC

2014

Published in July 2016
Updated in September 2016

Country General Information (WHO, 2013)

Total population:	21,898,000	Age group <15/>14 years, %:	35% / 65%
Gender ratio (% F/M):	49.1% / 50.9%	Life expectancy at birth in years (F/M):	78 / 73
GDP (PPP int \$)	No data	Number of 1st sub-national administrative level divisions, name:	14, Governorate
Income status:	Lower middle		

Epidemiology


	VL	ACL ^a	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	36	53876	No data	0
Number of relapse cases:	No data	1328	No data	0
Total number of cases:	36	55204	No data	0
Imported cases (n, %):	No data	No data	No data	N/A
Gender distribution (% F):	No data	54%	No data	N/A
Age group distribution (% <5/5-14/>14):	No data	(23/31/46)	No data	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.02	22.74	No data	N/A
Endemic 1st sub-national administrative level divisions for VL or CL (n):	7	14	No data	N/A
Population at risk ¹ (% n/total):	67% (14582000/21898000)	108% (23695000/21898000)	No data	N/A
Was there any outbreak?	No data	No data	No data	N/A
Number of new ² foci:	No data	No data	No data	N/A

N/A = not applicable VL = visceral leishmaniasis ACL = anthroponotic cutaneous leishmaniasis ZCL = zoonotic cutaneous leishmaniasis MCL = mucocutaneous leishmaniasis


Monthly distribution of new cases January-December

	2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL		3	1	7	2	3	5	4	3	1	1	1	5
CL		5493	5423	6335	5699	3892	3400	2317	2309	2492	3013	5441	8062



Number of new CL cases reported by month in 2013 and 2014



Number of new (primary) VL cases reported by month in 2013 and 2014



Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014



¹ Defined as "Number of people living in 1st sub-national administrative level endemic areas".

* No data available


Numerator is based on population data at governorate level from civil affairs records in 2010 while denominator is based on national estimates published in WHO country profiles for 2013.

² For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever


^a In the Syrian Arab Republic, both ACL and ZCL are endemic but information is only available as aggregated on "cutaneous leishmaniasis"

Distribution of new CL (left) and new (primary) VL (right) cases

Incidence of cutaneous leishmaniasis in the Syrian Arab Republic in 2014 at governorate level, per 10 000 population



Incidence of visceral leishmaniasis in the Syrian Arab Republic in 2014 at governorate level, per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available	Year latest national guidelines were published:	2010
Type of surveillance:	Integrated	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	Yes
Type of insecticide used for IRS:	Pyrethroid, WP and SC	Number of leishmaniasis health facilities:	220

Diagnosis

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	No data
Number of people screened passively for:	No data	No data	No data	No data
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides +/total cases):	No data	No data	No data	N/A
Proportion of positive slides (%, # slides +/total slides):	No data	No data	No data	N/A
Cases diagnosed clinically (%, # clinical cases/total cases):	No data	17% (9223/55204)	No data	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

* These indicators apply only for new (primary) VL cases

VL = visceral leishmaniasis

ACL = anthroponotic cutaneous leishmaniasis

ZCL = zoonotic cutaneous leishmaniasis

N/A = not applicable

RDT = rapid diagnostic test

HIV = human immunodeficiency virus

MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Sodium stibogluconate (SSG), meglumine antimoniate

TREATMENT OUTCOME

	VL
Proportion of relapse cases: ⁴	No data
Initial cure rate:	No data
Failure ⁵ rate:	No data
Case-fatality rate:	No data

⁴ A relapse case in this country is defined as: No definition available

⁵ A failure case in this country is defined as: No definition available